Abstract
Clinical studies were conducted on clindamycin-2-palmitate in the field of pediatrics and the following results were obtained.
1. A prompt improvement of laboratory data and clinical signs occurred in 23 cases out of 26 cases suspected bacterial infection.
2. It was very effective in 4 cases out of 6 cases of pneumonia due to Mycoplasma pneumoniae or cold-agglutination test positive pneumonia. The minimal growth inhibiting concentration against a Mycoplasma pneumoniae strain was 0.5 mcg/ml.
3. No particular side effects were detected in infants and children treated.
